Back to News
Market Impact: 0.2
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Source: Newswire
Healthcare & BiotechProduct Launches
A partnership combines the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, with potential reach to nearly 500,000 chronic disease patients. The release no longer mentions Cleveland Clinic Weston.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Starbucks serves up a solid quarter and full-year outlook. Why we're staying invested
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- Coinbase net income surges 66% in third quarter, benefiting from bitcoin investment gains
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- OpenAI-backed Thrive Holdings acquires ADT